3-苯基-5-吡啶-3-基苯胺 | 181633-34-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-苯基-5-吡啶-3-基苯胺
• 英文名称: 5-phenyl-3-(3-pyridyl)aniline
• 英文别名: 5-(Pyridin-3-yl)-[1,1'-biphenyl]-3-amine；3-phenyl-5-pyridin-3-ylaniline
• CAS: 181633-34-1
• 化学式: C₁₇H₁₄N₂
• 分子量: 246.312
• InChiKey: FIFJVOQZYRUYDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-苯基-5-吡啶-3-基苯胺 在 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 5-Methoxy-1-[5-phenyl-3-(pyrid-3-yl)phenylcarbamoyl]-6-trifluoromethyl Indoline
  参考文献：
  名称：

  Biarylcarbamoylindolines Are Novel and Selective 5-HT_2C Receptor Inverse Agonists:  Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent

  摘要：

  The evolution, synthesis, and biological activity of a novel series of 5-HT2C receptor inverse agonists are reported. Biarylcarbamoylindolines have been identified with excellent 5-HT2C affinity and selectivity over 5-HT2A receptors. In addition, (pyridyloxypyridyl)carbamoylindolines have been discovered with additional selectivity over the closely related 5-HT2B receptor. Compounds from this series are inverse agonists at the human cloned 5-HT2C receptor, completely abolishing basal activity in a functional assay. The new series have reduced P450 inhibitory liability compared to a previously described series of 1-(3-pyridylcarbamoyl)indolines (Bromidge et al. J. Med. Chem. 1998, 41, 1598) from which they evolved. Compounds from this series showed excellent oral activity in a rat mCPP hypolocomotion model and in animal models of anxiety. On the basis of their favorable biological profile, 32 (SB-228357) and 40 (SB-243213) have been selected for further evaluation to determine their therapeutic potential for the treatment of CNS disorders such as depression and anxiety.

  DOI：

  10.1021/jm990388c
• 作为产物：
  描述：

  1,3-二溴-5-硝基苯 在 盐酸 、 四(三苯基膦)钯 、 sodium carbonate 、 tin(ll) chloride 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 24.0h， 生成 3-苯基-5-吡啶-3-基苯胺
  参考文献：
  名称：

  Biarylcarbamoylindolines Are Novel and Selective 5-HT_2C Receptor Inverse Agonists:  Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent

  摘要：

  The evolution, synthesis, and biological activity of a novel series of 5-HT2C receptor inverse agonists are reported. Biarylcarbamoylindolines have been identified with excellent 5-HT2C affinity and selectivity over 5-HT2A receptors. In addition, (pyridyloxypyridyl)carbamoylindolines have been discovered with additional selectivity over the closely related 5-HT2B receptor. Compounds from this series are inverse agonists at the human cloned 5-HT2C receptor, completely abolishing basal activity in a functional assay. The new series have reduced P450 inhibitory liability compared to a previously described series of 1-(3-pyridylcarbamoyl)indolines (Bromidge et al. J. Med. Chem. 1998, 41, 1598) from which they evolved. Compounds from this series showed excellent oral activity in a rat mCPP hypolocomotion model and in animal models of anxiety. On the basis of their favorable biological profile, 32 (SB-228357) and 40 (SB-243213) have been selected for further evaluation to determine their therapeutic potential for the treatment of CNS disorders such as depression and anxiety.

  DOI：

  10.1021/jm990388c

文献信息

• Indole derivatives as 5-HT receptor antagonist
  申请人：SmithKline Beecham p.l.c.

  公开号：US20030105139A1

  公开（公告）日：2003-06-05

  The invention relates to heterocyclic compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders such as anxiety.

  本发明涉及具有药理活性的杂环化合物，其制备过程，含有它们的组合物以及它们在治疗中枢神经系统疾病如焦虑症方面的应用。
• ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE
  申请人：Samsung Electronics Co., Ltd.

  公开号：EP3851443A1

  公开（公告）日：2021-07-21

  An organometallic compound represented by Formula 1:          Formula 1     M(L1)n1(L2)n2 wherein, in Formula 1, M, L1, L2, n1, and n2 may be understood by referring to the descriptions of M, L1, L2, n1, and n2 respectively as disclosed herein.

  由式 1 表示的有机金属化合物： 式 1 M(L1)n1(L2)n2 其中，式 1 中的 M、L1、L2、n1 和 n2 可分别参照本文所公开的 M、L1、L2、n1 和 n2 的描述来理解。
• US6235758B1
  申请人：——

  公开号：US6235758B1

  公开（公告）日：2001-05-22
• Biarylcarbamoylindolines Are Novel and Selective 5-HT_2C Receptor Inverse Agonists:  Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent
  作者：Steven M. Bromidge、Steven Dabbs、David T. Davies、Susannah Davies、D. Malcolm Duckworth、Ian T. Forbes、Laramie M. Gaster、Peter Ham、Graham E. Jones、Frank D. King、Keith R. Mulholland、Damian V. Saunders、Paul A. Wyman、Frank E. Blaney、Stephen E. Clarke、Thomas P. Blackburn、Vicky Holland、Guy A. Kennett、Sean Lightowler、Derek N. Middlemiss、Brenda Trail、Graham J. Riley、Martyn D. Wood

  DOI：10.1021/jm990388c

  日期：2000.3.1

  The evolution, synthesis, and biological activity of a novel series of 5-HT2C receptor inverse agonists are reported. Biarylcarbamoylindolines have been identified with excellent 5-HT2C affinity and selectivity over 5-HT2A receptors. In addition, (pyridyloxypyridyl)carbamoylindolines have been discovered with additional selectivity over the closely related 5-HT2B receptor. Compounds from this series are inverse agonists at the human cloned 5-HT2C receptor, completely abolishing basal activity in a functional assay. The new series have reduced P450 inhibitory liability compared to a previously described series of 1-(3-pyridylcarbamoyl)indolines (Bromidge et al. J. Med. Chem. 1998, 41, 1598) from which they evolved. Compounds from this series showed excellent oral activity in a rat mCPP hypolocomotion model and in animal models of anxiety. On the basis of their favorable biological profile, 32 (SB-228357) and 40 (SB-243213) have been selected for further evaluation to determine their therapeutic potential for the treatment of CNS disorders such as depression and anxiety.